top of page

News Updates in Prostate Cancer 

Newsletters from Dr. Charles K. Metzger, MD, MBA

Each newsletter includes links to detailed articles

This paper discusses the results from the PACE-A trial, comparing quality of life outcomes from surgery vs stereotactic body radiotherapy (SBRT) among patients with intermediate-risk localized and low-risk prostate cancer.


March 18 2023

Sign up for the PROMISE Registry. Help yourself. Help your family. Help other P Ca fighters.

To learn more, visit 


March 4, 2023

This non-invasive means of determining presence of high risk Prostate Cancer will become easier to get via Iso-PSA Blood Test and may eliminate the need for some biopsies.


February 16, 2023

MRI-guided SBRT reduced both acute toxicity effects and decrements in quality-of-life measures when compared with CT-guided SBRT, according to findings published in JAMA Oncology


February 4, 2023

A little change of pace. Here's the Fall 2022 UCLA Urology Newsletter featuring our Nov. presenter Professor Leonard S. Marks, M.D. and his coworkers. We hope it will help you prepare for the Nov. presentation.


October 29, 2022

Just a brief glimpse of the literature regarding MRI before a biopsy. Not all studies agree but the consensus is in favor of the pre biopsy MRI fused to the ultrasound. Standard of care, to be sure.


August 12, 2022

This is a big step toward treatment intensification for men with both oligometastatic disease as well as more advanced metastatic disease.


August 6, 2022

This keeps coming up at our meetings, Dr Fuller endorses this as does UCLA.  Makes a lot of sense to prevent rectal issues with radiation.


June 24, 2022

This is a good reminder that androgen deprivation after salvage radiotherapy is the way to go, especially if the new drug is used (relugolix). Here are two articles for review.


June 18, 2022

Newest Aid to Help Guide Exact Margins in Prostate Surgery

An example of how modern technology is helping surgeons do a better job of finding proper anatomic margins to know they have resected all of the cancerous prostate.


June 3, 2022

Comparison of Micro-Ultrasound and Multiparametric MRI for Prostate Cancer

This is the nail in the coffin for the mri vs ultrasound debate. Not only will it get the process back into the urologist office, away from the radiologist there will be less reluctance to do guided biopsies.


May 14, 2022

Active Surveillance for Prostate Cancer - Updated Guidelines

Here is a current update from Johns Hopkins to their 2011 original article regarding active surveillance for prostate cancer. 


May 7, 2022

FDA Approves New Treatment for Metastatic Castration-Resistant Prostate Cancer

The FDA officially approved these agents which will be discussed in our next talk, on Thursday, April 24, 2022 at 7 pm. Please attend and find out how all this fits together.


April 22, 2022

An extensive review of the literature about pre treatment of advanced disease with different therapies (neoadjuvant) prior to surgery or radiation


April 9, 2022

Exciting Announcements

Here are two exciting new developments for the prostate cancer world. The first is treatment for men with metastatic prostate cancer that is hormone sensitive. Really impressive results. The second is the use of LU PSMA for treatment of end stage disease and its approval for use by the FDA in castrate resistant prostate cancer.


March 26, 2022

Informational Video Update on IsoPSA Test

This very informative video presentation by Dr. Eric A. Klein, MD is another example of progress in the decision about how to use PSA and who needs more testing.


March 13, 2022

Prostate-Specific Antigen–Based Screening Ushers in an Era of Change

This is a very interesting review of the history of PSA.  Lots of twists and turns in its life as a screening tool.  Using it wisely is really the key to its existence.


March 5, 2022

Although controversial, the trend is to treat the main tumor even if there is oligometastasis (less than five sites).


February 26, 2022

This is the near future of prostate imaging.


January 29, 2022

German hospitals are offering a 3-4 day inpatient treatment called Lutetium 177. 


January 10, 2022

The FDA has approved piflufolastat F 18 injection, a prostate-specific membrane antigen–targeted positron emission tomography imaging agent to identify suspected metastasis or recurrence of prostate cancer- it is finally official.


January 4, 2022

The Exablate system, which uses high intensity ultrasound to control locally-confined prostate cancer,  is very precise for the treatment of focal prostate cancer.


November 13, 2021

This is another step forward in the theranostics arena.


November 13, 2021

This is a succinct look at the field of immunotherapy as it relates to prostate cancer. It’s a great overview of current and future treatment options.


November 1, 2021

This article answers a question at the advance meeting of the value of pre op multi parametric MRI (this was pre PSMA work) in determining if surgery is the way to go. 


October 11, 2021

The PSMA-PET imaging agents Piflufolastat F 18 and Gallium 68 PSMA-11 are approved by the FDA for managing patients with prostate cancer


September 26, 2021

This very long article really is the answer to where MRI fits into the diagnostic scheme of elevated PSA.


September 11, 2021

It was just a matter of time before another promising agent was added to the PSMA.


Sept 3, 2021

The following articles help put to rest the value of MRI fused biopsy and compares it to the regular ultrasound guided biopsy


July 31, 2021

These articles show the amazing advances in the treatment of advanced prostate cancer.


July 17, 2021

Experts in prostate cancer discuss considerations for initiating ADT therapy after definitive treatment in patients with prostate cancer in the context of biochemical recurrence.


April 27, 2021

ORGOVYX, the drug that will eventually replace Lupron or Zoladex for the treatment of advanced prostate cancer, is now readily available. This is the only androgen deprivation therapy (ADT) medicine that is not given in the form of an injection.


April 10, 2021

The use of MRI guided transurethral approach to just treat a solitary lesion is now gaining traction as a way to do a more directed minimally invasive treatment.


April 3, 2021

A really good review of the use of active surveillance in all age groups. Emphasis on clinical guidelines and non-medical factors, like Vitamin D, low-dose statin, and frequent biomarkers for disease status.


March 18, 2021

Scientists are making great strides when it comes to the gene editing technique known as CRISPR. Scientists are confident that the treatment and prevention of prostate cancer using CRISPR technique holds tremendous potential.


March11, 2021

Scientists are making great strides when it comes to the gene editing technique known as CRISPR. Scientists are confident that the treatment and prevention of prostate cancer using CRISPR technique holds tremendous potential.


February 25, 2021

The incidence of prostate cancers that have spread to the bone at diagnosis has increased since the PSA test was taken off the guidelines of the U.S. Preventative Services Task Force (USPSTF). Some modification of this recommendation needs to be considered on a case-by-case basis.


February 25, 2021

A shorter course of stereotatic body radiotherapy (SBRT) has been shown to be effective in high-risk prostate cancer. The toxicity has been favorable and the cost is competitive.


February 16, 2021

Prostatepedia Magazine (quarterly) and the weekly Prostatepedia Digests feature informal conversations with doctors, patients, and activists about prostate cancer, and include links to publications and resources for prostate cancer. Use this link to Subscribe to Prostatepedia

bottom of page